Amareli tablet 2mg #30

Form

tableti

Dosage mg

2

Pack

30

Salt Tablet 2mg Composition: 1 tab. Glimepiride - 2 mg Excipients: Lactose, Sodium starch glycolate, Povidone 25000, Microcrystalline cellulose, Magnesium stearate, Iron oxide red (E 172) Indications: Insulin-independent diabetes mellitus (Type 2) when diet, therapy, and physical activity are ineffective. Additionally, Amaryl can be used in combination with insulin preparations in patients with insulin-independent diabetes mellitus Type 2. Dosage regimen: The initial and maintenance dose of the preparation is determined individually based on regular monitoring of blood and urine glucose levels. Regular monitoring of blood and urine glucose levels allows for the determination of primary or secondary resistance to the preparation. Initial dose and dose selection: At the beginning of treatment, 1 mg of Amaryl is prescribed once daily. If necessary, the daily dose can be gradually increased under regular blood glucose monitoring (at intervals of 1-2 weeks) according to the following scheme: 1 mg, 2 mg, 3 mg, 4 mg, 6 mg, and in exceptional cases 8 mg. For well-controlled diabetes mellitus patients, the daily dose range is from 1 to 4 mg. Only in individual patients is a therapeutic effect observed with a daily dose of Amaryl exceeding 6 mg. The maximum daily dose is 8 mg. Dose adjustment: When compensation of diabetes mellitus is achieved, insulin sensitivity increases. In this regard, the requirement for glimepiride may decrease during treatment. To prevent the development of hypoglycemia, it is necessary to temporarily reduce the dose or discontinue the preparation. Dose adjustment is also necessary in case of changes in the patient's body weight or lifestyle, or the occurrence of other factors that increase the risk of developing hypo- or hyperglycemia (see "Special Precautions"). Transferring patients from other blood glucose-lowering preparations to Amaryl: There is no exact correlation between the doses of Amaryl and other oral blood glucose-lowering preparations. When transferring from such preparations to Amaryl, the initial daily dose should be 1 mg (even in cases where the patient is transferred to Amaryl from the maximum dose of another oral blood glucose-lowering preparation). Any increase in the Amaryl dose should be made according to the recommendations presented in the "Initial dose and dose selection" subsection. The degree and duration of effectiveness of the previously used oral blood glucose-lowering preparation should be taken into account. Temporary discontinuation of treatment may be necessary to avoid an additive effect that increases the risk of hypoglycemia. Use in combination with insulin: In cases where normalization of blood glucose levels cannot be achieved with the maximum dose of Amaryl, it can be combined with insulin. In such cases, the last dose of Amaryl prescribed by the doctor remains unchanged. Insulin therapy is initiated with a minimum dose, followed by gradual increase and blood glucose monitoring. Combined therapy requires necessary medical supervision. The time and frequency of the daily dose are determined by the doctor, taking into account the patient's lifestyle. As a rule, the daily dose is prescribed as a single dose, immediately before breakfast. If the daily dose is not taken on time, the preparation should be taken immediately before the first substantial meal. Amaryl tablets should be taken whole, without chewing, with a sufficient amount of water (approximately 100-200 ml). It is very important not to miss a meal after taking Amaryl. Duration of treatment: As a rule, treatment with Amaryl is long-term. The preparation should be taken at the prescribed dose and time. Errors in the use of the preparation, for example, skipping a dose, can never be corrected by taking a higher dose later. The doctor and patient should agree in advance on the measures to be taken in case of such errors (e.g., skipping medication or a meal) or in situations where it is impossible to take the next dose of the preparation at the scheduled time. The patient should immediately inform the doctor in case of taking an overdose of the preparation. Contraindications: Hypersensitivity to glimepiride or any of the preparation's components (risk of hypersensitivity reactions); Insulin-dependent (Type 1) diabetes mellitus; Diabetic ketoacidosis, diabetic precoma, and coma; Severe liver dysfunction; Severe kidney dysfunction (including patients on hemodialysis). Pregnancy and lactation: The preparation is contraindicated in pregnant women. In case of planned pregnancy or conception, the woman should be switched to insulin therapy. Experimental studies have shown that glimepiride is excreted in breast milk. Therefore, Amaryl cannot be prescribed during lactation. The patient should switch to insulin or discontinue breastfeeding. Storage conditions and expiry date: The preparation should be stored at a temperature not exceeding 25°C, in a place protected from children.